




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07J 41/00, A61K 31/57</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/15568</b> <b>(43) International Publication Date:</b> 16 April 1998 (16.04.98)
<b>(21) International Application Number:</b> PCT/EP97/05426 <b>(22) International Filing Date:</b> 2 October 1997 (02.10.97) <b>(30) Priority Data:</b> MI96A002048      4 October 1996 (04.10.96)      IT <b>(71) Applicant (for all designated States except US):</b> NICOX S.A. [FR/FR]; 45, avenue Kléber, F-75116 Paris (FR). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> DEL SOLDATO, Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT). <b>(74) Agents:</b> SAMA, Daniele et al.; Sama Patents, Via G.B. Morgagni, 2, I-20129 Milano (IT).		<b>(81) Designated States:</b> AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF  <div style="text-align: center;">  </div> <p style="text-align: right;">(1)</p>		
<b>(57) Abstract</b>  Compounds of the general formula B-X <sub>1</sub> -NO <sub>2</sub> or their esters or salts, where B has structure (1) where there may be substituents in place of the hydrogens H in the CH group or two hydrogens H <sub>2</sub> in the CH <sub>2</sub> group shown in the general formula; R and R' are equal or different one from the other and may be hydrogen or linear or branched alkyls having from 1 to 4 carbon atoms, preferably R = R' = CH <sub>3</sub> ; B being a corticosteroid residue; R'' is -(CO-L) <sub>t</sub> -(X) <sub>t1</sub> - where t and t1 are integers equal or different one from the other and equal to 0 or 1; where L is a bivalent connecting group; X is equal to X <sub>0</sub> where X <sub>0</sub> = 0, NH, NR <sub>1C</sub> where R <sub>1C</sub> is a linear or branched alkyl having from 1 to 10 C atoms; or equal to X <sub>2</sub> where X <sub>2</sub> is equal to OH, CH <sub>3</sub> , Cl, N(-CH <sub>2</sub> -CH <sub>3</sub> ) <sub>2</sub> , SCH <sub>2</sub> F, SH; X <sub>1</sub> is a bivalent connecting bridge YO where Y is a C <sub>1</sub> -C <sub>20</sub> alkylene.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF

The present invention relates to preparation of new corticoid compounds.

In particular it relates to steroid-structured compounds having anti-inflammatory, immunodepressive and angiostatic activities (the so-called steroid anti-inflammatory drugs).

The compounds according to the present invention are therapeutically useful in the treatment of pathologic conditions where generally corticosteroid (corticoids) preparations are used, but with increased benefits.

This represents an unexpected advantage over the known corticoids products. In fact, by taking into account the various defined therapeutic uses of a specific product, it is always possible, with the new products of the present invention, to find a better combination of results with respect to the known corticoids. Contrary to any expectation the products of the present invention are characterised by the fact that they show an improved therapeutic profile: high activity combined with low side-effects.

Corticoids are well known as a first-choice pharmacological measure in the treatment of inflammatory disease. Drugs in this category - which include, for example, hydrocortisone, cortisone, prednisolone, prednisone, fludrocortisone,

tisone, desoxycorticosterone, methylprednisolone, triamcinolone, paramethasone, betametasone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, beclomethasone, acetoxypregnelone, etc. - have marked pharmacotoxicological effects on various organs. Because of this, the clinical use and discontinued use thereof cause a series of side effects, some of which are very severe. See for example Goodman & Gilman: "The Pharmaceutical Basis of Therapeutics", 9th Ed., pages 1459-1465, 1996.

These toxic effects include:

- those on bone which lead to changed cell metabolism and a high frequency of osteoporosis;
- those on the cardiovascular system which cause hypertensive reactions;
- those on the gastrointestinal tract which cause gastric damage.

See for instance Martindale: "The Extrapharmacopoeia", 30th Ed., pages 712-723, 1993.

According to the above mentioned art it appears to be almost impossible for therapeutic activities to be separated from side effects, see Goodman et al., as mentioned above, at page 1474.

Known in the art are non-steroid anti-inflammatory

drugs either with or without acidic ending, see patents WO 94/04484, WO 94/12463, WO 95/09831, WO 95/30641 for non-acidic ending and the patents therein mentioned for those with acidic ending.


However, it should be noted that steroid compounds are completely different from non-steroid compounds chemically, pharmacologically and biochemically as the pharmaco-toxicological mechanism of action of non-steroid products is based on inhibition of one or more cyclo-oxygenases (COX), while steroid products have nothing to share with COX and have more complex pharmaco-toxicological mechanisms of action which have not yet been fully explained.

It is well known that these two groups of compounds are listed in completely separate categories in international pharmacopoeias.

The applicant has surprisingly and unexpectedly found corticosteroids (corticoids) which are very effective, even superior to those in the known art, and have, at the same time, a higher tolerance than the known corticoids as unexpectedly they do not cause the above side effects, or when they do, these are lower.


An object of the present invention are corticosteroids and their use as anti-inflammatory, immunosuppressive and

angiostatic agents having the general formula:



or their esters or salts, where:


B has the following structure:



where, in place of the hydrogens H in the CH group or two hydrogens H<sub>2</sub> in the CH<sub>2</sub> group shown in the general formula, there may be the following substituents:

at position 1-2: there may be a double bond;


at position 2-3: there may be the following substituent:



at position 2: there may be Cl, Br;


at position 3: there may be CO, -O-CH<sub>2</sub>-CH<sub>2</sub>-Cl, OH;

at position 4-5: there may be a double bond;  
 at position 5-6: there may be a double bond;  
 at position 6: there may be Cl, F, CH<sub>3</sub>, -CHO;  
 at position 7: there may be Cl;  
 at position 9: there may be Cl, F;  
 at position 11: there may be OH, CO, Cl;  
 at position 16, there may be CH<sub>3</sub>, OH, =CH<sub>2</sub>;  
 at position 17: there may be OH, CH<sub>3</sub>, OCO(O)<sub>ua</sub>(CH<sub>2</sub>)<sub>va</sub>CH<sub>3</sub>, or



where ua is an integer equal to 0 or 1, va is an integer from 0 to 4;

at positions 16-17: there may be the following groups




R and R' are equal or different one from the other and may be hydrogen or linear or branched alkyls having from 1 to 4 carbon atoms, preferably R = R' = CH<sub>3</sub>;

B being a corticosteroid residue;

$R''$  is  $-(CO-L)_t-(X)_{t1}-$


where  $t$  and  $t1$  are integers equal or different one from the other and equal to 0 or 1, provided that they cannot be both equal to 0 when B contains no -OH groups;

the bivalent bridging group L is selected from:



where  $na$ ,  $n'a$  and  $n''a$  are equal or different one from the other and are integers from 0 to 6, preferably from 1 to 3;  $nb$ ,  $nb'$ ,  $n''b$  and  $n'''b$  are equal or different one from the other and are integers equal to 0 or 1;  $R_4$  and  $R_5$  are equal or different one from the other and are chosen from H, linear or branched alkyl having from 1 to 5 carbon atoms, preferably from 1 to 3;

X is equal to  $X_0 = 0$ , NH,  $NR_{1c}$  where  $R_{1c}$  is a linear or branched alkyl having from 1 to 10 C atoms; or equal to  $X_2$  where  $X_2$  is equal to OH,  $CH_3$ , Cl,  $N(-CH_2-CH_3)_2$ ,  $SCH_2F$ , SH,



$X_1$  is a bivalent connecting bridge chosen from:


- YO





where Y is a linear or whenever possible branched C<sub>1</sub>-C<sub>20</sub> alkylene, preferably having from 2 to 5 carbon atoms, or an optionally substituted cycloalkylene having from 5 to 7 carbon atoms;

- Y<sub>1</sub> selected from


-



where n<sub>3</sub> is an integer from 0 to 3;



where nf' is an integer from 1 to 6, preferably from 2 to 4;



where R<sub>1f</sub> = H, CH<sub>3</sub>, and nf is an integer from 1 to 6, preferably from 2 to 4.

The compounds which can be mentioned, and which are those preferred, are the ones listed below where B can be obtained according to the known processes of the art.

For example, the precursors and related processes described for example in The Merck Index, 12th Ed. of 1996, herein incorporated by reference, can be mentioned as precursors and related processes. The precursors (according to the Merck nomenclature) include the following, where H<sub>2</sub>, H, R, R', R'' have the meaning as defined in the compounds listed below: budesonide, hydrocortisone, alclometasone, algestone, beclomethasone, betamethasone, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, corticosterone, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortyn butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, loteprednol etabonate, medrysone, meprednisone, methylprednisolone, mometasone furoate, parametasone, prednicarbate, prednisolone, prednisolone 25-diethylaminoacetate, prednisolone sodium phosphate, prednisone,

prednival, prednylidene, rimexolone, triamcinolone, triamcinolone acetonide, 21-acetoxypregnenolone, cortivazol, amcinonide, fluticasone proprionate, mazipredone, tixocortol, triamcinolone hexacetonide.

The  $X_1$  connecting bridges as above defined are obtainable by using the methods known in the art as indicated above or by modifying the known methods by introducing  $X_1$  bridges when these are different from the connecting bridges described in the listed patents, using processes known in the art. Generally the connection between B and  $X_1$  is, as seen, of an ester or amide type (NH or  $NR_{1C}$ , as defined in X). Any well known synthetic route for forming these bonds can be used to form this connection.


In the case of esters, the most direct synthethic route includes:

reaction of acyl chlorides  $B-CO-Cl$  in halogen alcohols of the  $HO-Y_a-Cl$ ,  $HO-Y_a-Br$ ,  $HO-Y_a-I$  type, where  $Y_a$  is equal to Y or  $Y_1$  without the oxygen atom, in test conditions which are part of the known art.

The reaction products of formula  $B-CO-O-Y-Cl(Br, I)$  can also be obtained by reacting the sodium or potassium salts of salts acids  $B-CO-OH$  with dihalogen derivatives of the general formula  $Y_aCl_2$ ,  $Y_aBr_a$  or  $Y_aI_2$ ,  $ClY_aBr$ ,  $ClY_aI$ ,  $BrY_aI$ .


The reaction products are converted into the final products by reacting with  $\text{AgNO}_3$  in acetonitrile according to what is known in the literature.

The general scheme is as follows:




where  $\text{X}_1 = \text{Y}_a\text{O}$ .

The general scheme may also be as follows:




where  $\text{X}_1 = \text{Y}_a\text{O}$ .

In this case of amide, the synthetic sequence includes reaction of the same acyl chlorides  $\text{BCOCl}$  with aminoalcohols of the general formula  $\text{NH}_2\text{-Y}_a\text{-OH}$ ,  $\text{NHR}_{1c}\text{-Y}_a\text{-OH}$  to give amides of the general formula:




according to known methods.

Reaction of these amides with halogenating agents such as, for example  $\text{PCl}_5$ ,  $\text{PBr}_3$ ,  $\text{SOCl}_2$ , etc., gives the halogen derivatives of the general formula:




The latter give the final products  $\text{BX}_1\text{NO}_2$  by reacting with  $\text{AgNO}_3$  in acetonitrile according to methods known in the literature.

The sequence may be represented as:



where  $\text{Y}_a\text{O}$  is  $\text{X}_1$ .

An alternative route to ester formation is reaction of the sodium or potassium salts of the acids with the nitric esters of halogen alcohols of the general formula:




to directly give the products of the invention.

The reaction scheme is as follows:



where  $\text{Y}_a\text{O}$  is  $\text{X}_1$ .

Other synthetic routes similar to those described above include those in which the dihalogen derivative  $\text{Br}_2\text{Y}_a$  is reacted with enolates. The reaction products are then converted by reacting with  $\text{AgNO}_3$  in acetonitrile according to the above reaction. The general scheme is shown for an -OH in group B, of the type  $-\text{CH}_2\text{-OH}$ ,  $=\text{CH-OH}$ , is as follows:



The processes to obtain these  $\text{X}_1$  connecting groups are described in patent application WO95/30641 herein incorporated by reference.

As said above the compounds of the invention of

formula B-X<sub>1</sub>-NO<sub>2</sub> or their pharmaceutical compositions, are used for the treatment of diseases in which the well known corticoids products are employed.


In particular, it can be specifically mentioned the use in respiratory disorders, e.g. antiasthmatic, the use as antiarthritic, antipruritic, antipsoriatic, antieczematic; the use in vascular disorders, e.g. as angiostatic, the use in immunology disorders, e.g. as immunosuppressive.


The compounds, or their compositions, of the present invention can be administered for example by oral, rectal (intestinal disorders), parenteral route or by local (dermal, topical, transdermal, ocular, inhalatory, etc.) application.

The following examples are given only for illustrative purpose as an explanation but not as a limitation of the present invention.

#### EXAMPLE 1

CHEMICAL SYNTHESIS: preparation of hydrocortisone nitroderivative (HCN)



EXAMPLE 1APreparation of hydrocortisone (4-chloro)butanoate

4 portions of 4-chlorobutanoylchloride (0.32 ml x 4) and triethylamine (0.3 g x 4) were added in 24 hours to a solution of hydrocortisone (1 g) in  $\text{CHCl}_3$ , dried over  $\text{P}_2\text{O}_5$ , and stirred for 3 days. The solution was treated with water, the organic phase was separated, dried ( $\text{Na}_2\text{SO}_4$ ) and deprived of the solvent at reduced pressure. The crude residue was ground with hexane and  $\text{CH}_2\text{Cl}_2$  to give a white solid with a 53% yield by weight, which had a melting point (m.p.) of  $155^\circ\text{C}$ .

The product was characterised by mass spectrometry:  $M^+493$ .

$^1\text{H}$  NMR (300 MHz  $\text{CDCl}_3$ ): 0.95 (3H, s,  $\text{CH}_3$ ), 1.45 (3H, s,  $\text{CH}_3$ ), 2.12 (2H, t,  $\text{CH}_2$  in 2), 2.6 (2H, t,  $\text{CH}_2\text{COO}$ ), 3.65 (2H, t,  $\text{CH}_2\text{Cl}$ ), 4.45 (1H, m,  $\text{CHOH}$ ), 4.35 and 5.05 (2H, 2d,  $\text{COCH}_2\text{O}$ ), 5.70 (1H, s, olefin H).

Preparation of hydrocortisone (4-nitroxy)butanoate

$\text{AgNO}_3$  (0.2 g) was added to a solution of hydrocortisone-

4-chlorobutanoate prepared as above (0.23 g) in acetonitrile (70 ml) and refluxed for 16 hours. The solution was deprived of the solvent at reduced pressure and chromatographed on silica gel using a solution of ethyl acetate and  $\text{CH}_2\text{Cl}_2$  (3:7) as an eluant.


Cortisone 4-nitroxybutanoate was recovered from the head fractions.

The product was characterised by  $^1\text{H}$  NMR (300 MHz  $\text{CDCl}_3$ ): 0,95 (3H, s,  $\text{CH}_3$ ), 1.45 (3H, s,  $\text{CH}_3$ ), 2.12 (2H, t,  $\text{CH}_2$  in 2), 2.6 (2H, t,  $\text{CH}_2\text{COO}$ ), 4.45 (1H, m,  $\text{CHOH}$ ), 4.45 (2H, t,  $\text{CH}_2\text{O}-\text{NO}_2$ ), 4.35 and 5.05 (2H, 2d,  $\text{COCH}_2\text{O}$ ), 5.68 (1H, s, olefin H).

#### EXAMPLE 1B

The product from Example 1A was also prepared using another synthetic route.

#### Preparation of hydrocortisone 4-bromobutanoate



Five portions of 4-bromobutanoylchloride (0.35 ml x 5) and potassium carbonate (0.4 g x 5) were added in 24 hours to a solution of hydrocortisone (1 g) in  $\text{CHCl}_3$ , dried over  $\text{P}_2\text{O}_5$  and stirred for 5 days. The solution was treated with water,



the organic phase was separated, dried ( $\text{Na}_2\text{SO}_4$ ) and deprived of the solvent at reduced pressure.

Preparation of hydrocortisone 4-nitroxybutanoate (HCN)

$\text{AgNO}_3$  (0.2 g) was added to a solution of hydrocortisone 4-bromobutanoate prepared as above (0.23 g) in acetonitrile (70 ml) and stirred for 48 hours at room temperature.

The solution was deprived of the solvent at reduced pressure and chromatographed on silica gel using a solution of ethyl acetate and  $\text{CH}_2\text{Cl}_2$  (3:7) as an eluant.

Cortisone 4-nitroxybutanoate was recovered from the head fractions and characterised by mass spectrometry:  $M^+$  493. The spectrum was the same as that shown in Example 1A.

EXAMPLE 2

Evaluation of safety and activity

The products were administered in a 2%-by-weight carboxymethyl cellulose suspension during in vivo tests, while a 0.1%-by-weight dimethylsulphoxide suspension was used for in vitro studies.

The test groups always included 8 samples (except when differently stated in the examples) for adequate statistical evaluation, to be carried out when necessary according to common statistical procedures.

**EXAMPLES 2A****Acute toxicity study**

The acute toxicity of the product from Example 1A was roughly evaluated by orally administering a single dose of substance to a group of 10 mice of the Swiss strain.

Death incidence and appearance of toxic symptoms were observed during a period of 14 days after the compound administration.

The animals showed no sign of apparent toxicity even after administration of a 50 mg/kg dose.

**EXAMPLE 2B****Study of antiarthritic activity**

Adjuvant arthritis was induced in male rats of Lewis strain, weighing  $170 \pm 15$  g by intracaudal injection of 0.6 mg of Mycobacterium butyricum (Difco) suspended in 0.1 ml of mineral oil. The animals were treated with a vehicle made up of an intraperitoneal (i.p.) 2%-by-weight suspension of carboxymethyl cellulose in water, with intraperitoneal hydrocortisone of HCN (a suspension as described above) at doses of 5 mg/kg or doses of 10 mg/kg, starting from the first day after mycobacterium inoculation.

Arthritis development was assessed 21 days later. To the arthritic lesions an arbitrary score was assigned accor-

ding to the following scale:

- hind limbs: 0 to 7 for each (0 for no lesions and 7 for most severe lesions);
- forelimbs: 0 to 4.5 for each (0 for no lesions and 4.5 for most severe lesions);
- tail: 0 to 5 (0 for no lesions and 5 for most severe lesions);
- ears: 0 to 2 for each (0 for no lesions and 2 for most severe lesions);
- nose and eyes: 0 to 1 ofr each (0 for no lesions and 1 for most severe lesions).

The results were expressed as a percentage of inhibition compared to the value obtained in the control group (animals treated withe the vehicle alone).

The result are shown in Table 1.

TABLE 1 - STUDY OF ANTIARTHRITIC ACTIVITY OF COMPOUND HCN VERSUS HYDROCORTISONE IN RATS

COMPOUND	DOSE (mg/kg)	ANTIARTHRITIC ACTIVITY (%)
HYDROCORTISONE	5	40
HYDROCORTISONE	10	55
HCN	5	45
HCN	10	62

As shown by the results in Table 1, the test products were capable of similarly inhibiting development of the arthritic process caused by mycobacterium. However, being the tolerability of HCN much higher than that of hydrocortisone (see ex 2C below), the results in terms of activity are much better in the case of HCN (see for comparison 40% of antiarthritic activity obtained with 5 mg/kg hydrocortisone with respect to 62% obtained with 10 mg/kg HCN).

#### EXAMPLE 2C

##### Study of gastric tolerability (safety)

Male Sprague-Dawley rats fasted for 24 hours were treated with 5 to 10 mg/kg of intraperitoneal hydrocortisone or HCN.

Twenty-four hours later the animals were sacrificed, the stomach was removed and tissue was grossly examined for the presence of lesions as described by Del Soldato et al.: "The influence of fasting and cimetidine on the relationship between ulcerogenic and anti-inflammatory properties of cimetidine", Br.J.Pharmacol. 67, 33-37, 1979. The degree of severity of the disease was evaluated according to common methods and expressed as arbitrary values. The results are shown in Table 2.

TABLE 2 - STUDY OF GASTRIC TOLERABILITY OF COMPOUND HCN  
VERSUS HYDROCORTISONE IN RATS

COMPOUND	DOSE (mg/kg)	GASTRIC TOLERABILITY
HYDROCORTISONE	5	2.0
HYDROCORTISONE	10	3.5
HCN	5	0.5*
HCN	10	1.2*

Data are expressed as arbitrary values according to the following scale: 0 = absent; 1 = mild lesions; 2 = moderate lesions; 3 = punctiform ulcers; 4 = severe and numerous ulcers.

\*  $P < 0.05$  (where P is probability) compared to corresponding value in group treated with hydrocortisone.

As shown in Table 2, the rats treated with hydrocortisone exhibited a marked disease in the gastrointestinal tract, varying in severity from mucosal erosion to ulcer involving the muscle layer, wall adhesions, ascites, peritonitis. In the other groups treated with the vehicle alone or HCN, the damage was much lower or even absent.

#### EXAMPLE 2D

##### Study of nitroxysynthetase activity

The nitroxy-synthetase inhibiting activity induced by lipopolysaccharide (LPS) was determined in rat neutrophils

and stomach after administration of one of the test compounds and compared with that obtained after treatment with the suspending vehicle only. Wistar rats fasted for 24 hours before treatment received one of the test compounds intraperitoneally (10 mg/kg) or LPS intravenously (caudal vein) (5 mg/kg). Four hours later the animals were sacrificed. Blood for neutrophil isolation and stomach were removed.

Enzymatic activity was determined according to the method described by Assreuy et al.: "Feedback inhibition of nitric oxide synthase activity by nitric oxide", Br.J.Pharmacol. 108, 833-7, 1993. The results are shown in Table 3.

TABLE 3 - STUDY OF NITROXYSYNTHETASE ACTIVITY IN COMPOUND HCN VERSUS HYDROCORTISONE IN RATS

COMPOUND	DOSE (mg/kg/i.p.)	NITROXYSYNTHETASE ACTIVITY <sup>a</sup>
VEHICLE	-	100
HYDROCORTISONE	10	55*
HCN	10	62*

<sup>a</sup> per cent inhibition compared to group treated with vehicle alone

\* p < 0.05 compared to corresponding value in group treated with vehicle.

As shown by Table 3, both test products proved to be very effective in inhibiting nitroxysynthetase compared to

the group treated with the vehicle alone.

## EXAMPLE 2E

### Study of bone toxicity

Bone tissues (parietal bone from rat foetus) grown in vitro according to the method described by Doherty et al. ("The effect of glucocorticoids on osteoblast function. The effect of corticosterone on osteoblast, expression of beta-1 integrins", Journal of Bone and Joint Surgery, Series A77/3, 396-404, 1995) was used. Hydrocortisone or HCN or the vehicle were incubated at concentrations of 100 nmol.

Ninety six hours later calcium content and bone dry weight were measured.

The results are shown in Table 4.

TABLE 4 - EFFECT OF HCN AND HYDROCORTISONE ON BONE GROWTH IN RATS

TREATMENT	(nmol)	Calcium $\Delta^{\circ}\%$	DRY TISSUE WEIGHT $\Delta^{\circ}\%$
VEHICLE	-	310	160
HYDROCORTISONE	10	70*	95*
HCN	10	287	149

° Compared to initial value (incubation time zero)

\*  $p < 0.05$  compared to values obtained in control group (vehicle)

As shown in Table 4, a significant increase in tissue dry weight and increased calcium were observed after incuba-

tion with the vehicle or HCN. After incubation with hydrocortisone, the calcium content decreased and the bone dry weight did not increase. This shows that this treatment with hydrocortisone adversely affected bone growth.

#### EXAMPLE 2F

##### Study of some cardiovascular parameters

The effect of the test products on some cardiovascular parameters was studied in conscious Long Evans rats (350 to 450 g) which were appropriately monitored, as described by Gardiner et al.: "Influence of dexamethasone on the regional haemodynamic responses to lipopolysaccharide in conscious rats: effect of the non-selective endothelin antagonist: SB 209670", Br.J. Pharmacology 117, 49P, 1996. The animals were treated with the vehicle (physiologic saline solution, 0,9% sodium chloride, s.c.) subcutaneous hydrocortisone or HCN (10 mg/kg). Heart rate and blood pressure were recorded 4 hours after treatment.

Table 5 shows the data obtained as per-cent variation from control values.

TABLE 5 - STUDY OF COMPOUND HCN VERSUS HYDROCORTISONE IN SOME CARDIOVASCULAR PARAMETERS IN RATS



COMPOUND	DOSE (mg/kg)	HEART RATE <sup>a</sup> (%)	BLOOD PRESSURE <sup>b</sup>
VEHICLE	-	100	160
HYDROCORTISONE	10	89 <sup>*</sup>	115 <sup>*</sup>
HCN	10	98	103

\* P < 0.05 compared to group treated with vehicle

<sup>a</sup> per-cent change compared to value recorded in group treated with vehicle alone (324±7 beats per minute)

<sup>b</sup> per-cent change compared to value recorded in group treated with vehicle alone (101±2 mm Hg)

The results in Table 5 show that the product of the invention HCN does not affect the cardiovascular parameters measured. On the contrary, hydrocortisone used in the known art shows significant pressure as well as cardiac changes.

#### EXAMPLE 2G

##### Study of angiostatic activity in rats

Male Wistar rats weighing 180 to 200 g were used according to the procedure described by Andrade et al.: "Quantitative in vivo studies on angiogenesis in a rat sponge model", Brit. J. Exp. Pathol. 68, 755-766, 1987. The neovascularisation was evaluated in relation to blood flow by implanting a small sponge in the subcutaneous tissue for 14 days and determining <sup>133</sup>Xe clearance. Briefly, an amount of <sup>133</sup>Xe equal to 10µl was injected into the sponge using a small polyethylene cannula. The residual radioactivity from

implantation using a gamma ray detector and the  $^{133}\text{Xe}$  clearance for 6 minutes was measured as a percentage of the initial value. The validity of this method for measuring neovascularisation was recently demonstrated by HU et al.: "Correlation of  $^{133}\text{Xe}$  clearance, blood flow and histology in the rat sponge model for angiogenesis. Further studies with angiogenic modifiers", Lab. Invest. 72, 601-610, 1995.

The test compounds were administered by the subcutaneous route at a dose of 10 mg/kg from day 1 to day 13 after implantation.  $^{133}\text{Xe}$  was measured at day 14 from subcutaneous implantation, the animals were then sacrificed and the weights of thymus and spleen were recorded.

Table 6 shows the data obtained regarding the effect of the test products on neovascularisation and on the weight of spleen and thymus.

TABLE 6 - EFFECT OF HCN AND HYDROCORTISONE ON  $^{133}\text{Xe}$  CLEARANCE AND WEIGHT OF SPLEEN AND THYMUS AT DAY 14

TREATMENT	$^{133}\text{Xe}$ (%)	SPLEEN (mg)	THYMUS (mg)
VEHICLE	42	663±25	313±28
HYDROCORTISONE	33	642±32	185±17*
HCN	22*	673±38	297±31

\* P < 0.05 compared to values obtained in control group (vehicle)

As evident, HCN proved to be capable of exerting a

marked angiostatic effect without changing the weight of spleen or thymus, differently from the reference product.

As it is clear from the whole of the data shown in Tables 1 to 6, the pharmacodynamic activity - anti-arthritic, immunosuppressive and antiangiogenic activities - and tolerability of the nitroderivative are superior than those of the corticoid from the known art.

### EXAMPLE 3

#### Dexamethasone 21-(4-bromobutyrate) [II]

Dexamethasone [I]	3.5 g	8.9 mmol
4-Bromobutyryl chloride	4.06 ml	35 mmol
Potassium carbonate	4.9 g	35 mmol
Tetrahydrofuran	70ml	

The solution of compound I in tetrahydrofuran is portionwise treated with 4-bromobutyryl chloride (0.81 ml x 5) and potassium carbonate (0.98 g x 5) during 7 hours. The mixture is stirred overnight, the solvent is evaporated under vacuum and the residue is treated with ethyl ether and water. The organic layer is separated, washed with water and dried with anhydrous sodium sulfate. After evaporation of the solvent, the residue is purified by silica gel flash column chromatography eluting with t.butyl methyl ether - hexane 1-1 to give:

- less polar compound 1.0 g;
- derivative II 1.5 g (m.p. 184-187 °C; yield 31%)

TLC: t.butyl methyl ether-hexane 2-1.

Dexamethasone 21-(4-nitrooxybutyrate) [III] (compound DXN)

Compound II	1.5 g	2.7 mmol
Silver nitrate	2.4 g	14.1 mmol
Acetonitrile	250 ml	




The mixture of compound II and silver nitrate in acetonitrile is refluxed for 7 hours. After filtration of inorganic salts, the solvent is evaporated under vacuum and the residue is treated with ethyl ether. The organic layer is twice washed with water, dried with anhydrous sodium sulfate and evaporated under vacuum. The residue is poured into ethyl ether and filtered to give 1.27 g of pure compound III as a white solid (m.p. 183-185° C; yield 90%)

TLC: t.butyl methyl ether-hexane 2-1.

The following forms are enclosed:

- synthetic scheme;
- NCX 1005 batch 1;
- NCX 1005/1 analysis.

SYNTHETIC SCHEME FOR THE PREPARATION  
OF DEXAMETHASONE 21-(4-NITROOXIBUTYRATE)



**EXAMPLE 4****Study of the activity on leucocyte accumulation**

Male Swiss albino mice (27-33 g) maintained on a standard chow pellet diet and tap water ad libitum were used. The experiment was done as previously described by Perretti et al. (Perretti M., Solito E., Parente L., "Evidence that endogenous interleukin-1 is involved in neutrophil migration in acute experimental inflammation in rats and mice", Agents Actions, 35,71,1992). Animals were pretreated with zymosan (1mg/0.5ml) i.p. at time 0. Two hours later DEXAMETHASONE (1 mg/kg) (Ex3-I), DXN (Ex3-III) (1mg/kg) or phosphate buffered saline (PBS) was given intravenously. The animals were sacrificed at 4 and 24h the lavage fluids were collected and differential cell counts were performed following staining in Turk's.

Table 7 reports results obtained on the inhibitory effect of the tested compounds on zymosan-induced leucocyte migration in mice. As can be observed the nitroderivative steroid is much more active than dexamethasone.

TABLE 7-Inhibition of neutrophil and monocyte recruitment by DEXAMETHASONE and DXN (1mg/kg) given 2h i.v. after zymosan (1mg/0.5ml) i.p.

treatment	PMNx10 <sup>6</sup> /mouse (time 4h)	% reduction	mono-mØ x10 <sup>6</sup> /mouse (time 24h)	%reduction
vehicle	10.1±1.0	.....	8.8±1.3	.....
DXN	4.5±0.3	55.4	4.5±0.6	48.8
DEXAMETHASONE	6.4±0.4	36.6	6.3±0.2	28.4

**EXAMPLE 5****Study of the anti-proliferative activity in human airway  
smooth muscle cells**

Human airway smooth muscle cells were cultured by standard explant methods. Tissues were collected into sterile pots containing PBS and penicillin and streptomycin. Under sterile tissue culture conditions, tissues were cut into small pieces (approximately 1 mg weight) and placed into standard medium containing 20% fetal calf serum (FCS) for several days (medium changed every 2-4 days). <sup>3</sup>H-thymidine was measured in the DNA fraction of cells cultured into 48 well plates. Cells were cultured to confluence in the medium containing 10% FCS. Cells were deprived of serum for 24h before the addition of 10% FCS, together with different concentration of steroids. After 24h, <sup>3</sup>H-thymidine was added to the cells for 4h. Cells were washed with phosphate buffered saline and ethanol. The DNA was extracted with sodium hydroxide solution and the <sup>3</sup>H material counted by scintillation. The data represent observations made in triplicate

wells from smooth muscle cultured from one healthy lung donor. Table 8 reports results obtained on the inhibitory effect of the tested compounds on human airway smooth cell proliferation. As can be observed the nitroderivative steroid is much more active than dexamethasone.

TABLE 8-Inhibition of human airway smooth cell mitogenesis by different concentrations of DEXAMETHASONE and DXN

Treatment	Concentration (logM)	<sup>3</sup> H-thymidine (CPMx1000)
DEXAMETHASONE	-5	14.1
	-7	15.0
DXN	-5	10.8
	-7	12.6


#### CONCLUSIONS

As can be observed from results reported above, both activity and safety of the new nitroderivatives are better than those owned by the precursor steroids.




## CLAIMS

1. Compounds of the general formula:



or their esters or salts, where:


B has the following structure:



where, in place of the hydrogens H in the CH group or two hydrogens H<sub>2</sub> in the CH<sub>2</sub> group shown in the general formula, there may be the following substituents:

at position 1-2: there may be a double bond;

at position 2-3: there may be the following substituent:




at position 2: there may be Cl, Br;

at position 3: there may be CO, -O-CH<sub>2</sub>-CH<sub>2</sub>-Cl, OH,  
 at position 4-5: there may be a double bond;  
 at position 5-6: there may be a double bond;  
 at position 6: there may be Cl, F, CH<sub>3</sub>, -CHO;  
 at position 7: there may be Cl;  
 at position 9: there may be Cl, F;  
 at position 11: there may be OH, CO, Cl;  
 at position 16: there may be CH<sub>3</sub>, OH, =CH<sub>2</sub>,  
 at position 17: there may be OH, CH<sub>3</sub>, OCO(O)<sub>ua</sub>(CH<sub>2</sub>)<sub>va</sub>CH<sub>3</sub>,  
 or



where ua is an integer equal to 0 or 1, va is an integer from 0 to 4;

at position 16-17: there may be the following groups




R and R' are equal or different one from the other and  
 may be hydrogen or linear or branched alkyls having

from 1 to 4 carbon atoms, preferably  $R = R' = CH_3$ ,


B being a corticosteroid residue;

$R''$  is  $-(CO-L)_t-(X)_{t1}-$

where  $t$  and  $t1$  are integers equal or different one from the other and equal to 0 or 1, provided that they cannot be both equal to 0 when B contains no -OH groups; the bivalent bridging L is chosen from:



where  $na$ ,  $n'a$ , and  $n''a$  are equal or different one from the other and are integers from 0 to 6, preferably from 1 to 3,  $nb$ ,  $n'b$ ,  $n''b$  and  $n'''b$  are equal or different one from the other and are integers equal to 0 or 1;  $R_4$  and  $R_5$  are equal or different one from the other and are chosen from H, linear or branched alkyl having from 1 to 5 carbon atoms, preferably from 1 to 3; X is equal to  $X_0$  where  $X_0 = O, NH, NR_{1c}$  where  $R_{1c}$  is a linear or branched alkyl having from 1 to 10 C atoms; or equal to  $X_2$  where  $X_2$  is equal to OH,  $CH_3$ , Cl,  $N(-CH_2-CH_3)_2$ ,  $SCH_2F$ , SH,




$X_1$  is a bivalent connecting bridge chosen from:

- YO

where Y is a linear or whenever possible branched  $C_1$ - $C_{20}$  alkylene, preferably having from 2 to 5 carbon atoms, or an optionally substituted cycloalkylene having from 5 to 7 carbon atoms;


-  $Y_1$ , chosen from

-




where  $n_3$  is an integer from 0 to 3;

-




-



where  $nf'$  is an integer from 1 to 6, preferably from 2 to 4;

-



where  $R_{1f} = H, CH_3$  and  $nf$  is an integer from 1 to 6, pre-

ferably from 2 to 4.

2. Compounds according to Claim 1, in which precursors include the following, where  $H_2$ , H, R, R', R'' are as defined in the compounds listed below: budesonide, hydrocortisone, alclometasone, algestone, beclomethasone, betamethasone, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, cortisone, corticosterone, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, fluzacort, flucoronide, flumetasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortyn butyl, flucortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, formocortal, falcinonide, halobetasol propionate, halomethasone, halopredone acetate, hydrocortamate, loteprednol etabonate, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethasone, prednicarbate, prednisolone, prednisolone 25-diethylaminoacetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, triamcinolone, triamcinolone acetonide, 21-acetoxypregnenolone, cortivazol, amcinonide, fluticasone propionate, mazipredone, tixocortol, triamcinolone hexacetonide, where R'' is as

defined in Claim 1.


3. Compounds or compositions according to Claim 1 to be used as medicaments.
4. Use of the compounds or compositions in Claim 2 for the preparation of medicaments such as corticoids.
5. Use of the compounds or compositions according to Claim 4 for the preparation of medicaments such as anti-arthritic.
6. Use of the compounds or composition according to Claim 4 for the preparation of medicaments such as immunodepressives.
7. Use of the compounds or compositions according to Claim 4 for the preparation of medicaments such as angiostatics.
8. Use of the compounds or compositions according to Claim 4 for the preparation of medicaments such as antiasthmatics.
9. Use of the compounds or compositions according to Claim 4 for dermatology disorders.
10. Use of the compounds or compositions according to Claim 4 for ocular disorders.
11. Use of the compounds or compositions according to Claim 4 for intestinal disorders.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07J 41/00, A61K 31/57</b>		<b>A3</b>	(11) International Publication Number: <b>WO 98/15568</b>
			(43) International Publication Date: 16 April 1998 (16.04.98)
(21) International Application Number: PCT/EP97/05426		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 October 1997 (02.10.97)		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: MI96A002048 4 October 1996 (04.10.96) IT			
(71) Applicant (for all designated States except US): NICOX S.A. [FR/FR]; 45, avenue Kléber, F-75116 Paris (FR).			
(72) Inventor; and (75) Inventor/Applicant (for US only): DEL SOLDATO, Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT).			
(74) Agents: SAMA, Daniele et al.; Sama Patents, Via G.B. Morgagni, 2, I-20129 Milano (IT).			
		(88) Date of publication of the international search report: 18 June 1998 (18.06.98)	

(54) Title: NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF



(1)

## (57) Abstract

Compounds of the general formula B-X<sub>1</sub>-NO<sub>2</sub> or their esters or salts, where B has structure (1) where there may be substituents in place of the hydrogens H in the CH group or two hydrogens H<sub>2</sub> in the CH<sub>2</sub> group shown in the general formula; R and R' are equal or different one from the other and may be hydrogen or linear or branched alkyls having from 1 to 4 carbon atoms, preferably R = R' = CH<sub>3</sub>; B being a corticosteroid residue; R'' is -(CO-L)<sub>t</sub>-(X)<sub>t1</sub>- where t and t1 are integers equal or different one from the other and equal to 0 or 1; where L is a bivalent connecting group; X is equal to X<sub>0</sub> where X<sub>0</sub> = 0, NH, NR<sub>1C</sub> where R<sub>1C</sub> is a linear or branched alkyl having from 1 to 10 C atoms; or equal to X<sub>2</sub> where X<sub>2</sub> is equal to OH, CH<sub>3</sub>, Cl, N(CH<sub>2</sub>-CH<sub>3</sub>)<sub>2</sub>, SCH<sub>2</sub>F, SH; X<sub>1</sub> is a bivalent connecting bridge YO where Y is a C<sub>1</sub>-C<sub>20</sub> alkylene.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



## INTERNAT L SEARCH REPORT

International Application No.  
PCT/EP 97/05426A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07J41/00 A61K31/57

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07J A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 22 22 491 A (RICHTER GEDEON VEGYESZETI RT) 16 November 1972 see page 4, paragraph 2; examples 2-5,9,10 ---	1-11
Y	DE 16 43 034 A (SCHERING A.G.) 6 May 1971 see page 1 see page 3, paragraph 2; examples 6-12 ---	1-11
Y	BAYUNOVA V I ET AL: "SYNTHESIS AND BIOLOGICAL ACTIVITY OF ALKYL SUCCINATES OF PREDNISOLONE" PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 14, no. 12, 1981, pages 878-880, XP002035558 see the whole document --- -/--	1-11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

3 April 1998

Date of mailing of the international search report

20.04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05426

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HAYASHI H ET AL: "1,4:3,6-DIANHYDROHEXITOL NITRATE DERIVATIVES. II. 1) SYNTHESIS AND ANTIANGINAL ACTIVITY OF ARYL- OR ARYLCARBONYLPYPERAZINE DERIVATIVES 2)" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 41, no. 6, June 1993, pages 1100-1110, XP000611905 see page 1100, column 1, paragraph 1 ---	1-11
X	US 3 494 941 A (LEDIG KURT W ET AL) 10 February 1970 see examples 2,4 ---	1,3-11
A	HODOSAN F ET AL: "Nitrate esters of steroid hormones and related compounds. Preparation and biological properties" ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH., vol. 19, no. 4, 1969, AULENDORF DE, pages 684-685, XP002061312 see page 684, column 2 ---	1-11
Y	FR 2 274 309 A (PLURICHEMIE ANSTALT) 9 January 1976 see page 29 ---	1-11
Y	US 2 990 401 A (S. BERNSTEIN ET AL) 27 June 1961 see example 18 ---	1-11
Y	TEUTSCH G ET AL: "Design of ligands for the glucocorticoid and progestin receptors" BIOCHEM. SOC. TRANS., vol. 19, no. 4, 1991, pages 901-908, XP002061313 see page 903; example 5 ---	1-11
Y	GB 1 544 512 A (SQUIBB & SONS INC) 19 April 1979 see whole document, in particular examples 3,4 --- -/--	1-11

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 97/05426

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 099, no. 11, 12 September 1983 Columbus, Ohio, US; abstract no. 088460, LI Z ET AL: "Synthesis of 5-pregnene-3.beta.,17.alpha.-diol-20-one 3-acetate 17.alpha.-carboxylic acid esters, and studies on their structure-activity relations" XP002061315 see abstract & YAOXUE XUEBAO (YHHPAL,05134870);83; VOL.18 (2); PP.119-24, BEIJING MED. COLL.;DEP. PHARM.; BEIJING; PEOP. REP. CHINA (CN), ---	1-11
Y	CHEMICAL ABSTRACTS, vol. 097, no. 11, 13 September 1982 Columbus, Ohio, US; abstract no. 092623, LI Z ET AL: "Synthesis of 3.beta.-hydroxypregn-5-en-20-one A and B ring derivatives and studies on their structure-activity relationships" XP002061316 see abstract & YAOXUE XUEBAO (YHHPAL,05134870);82; VOL.17 (4); PP.265-74, BEIJING MED. COLL.;DEP. PHARM.; BEIJING; PEOP. REP. CHINA (CN), ---	1-11
Y	FR 1 561 908 A (THE UPJOHN COMPANY) 24 February 1969 see the whole document ---	1-11
Y	M. HELLER ET AL: "16-Hydroxylated Steroids. XXII. The Preparation of the 16-Methyl Ether of Triamcinolone" JOURNAL OF ORGANIC CHEMISTRY., vol. 27, no. 1, 18 January 1962, EASTON US, pages 328-331, XP002061314 see page 329, column 2, compounds Ic and If and "Bioassays" section ---	1-11
Y	CHEMICAL ABSTRACTS, vol. 070, no. 15, 14 April 1969 Columbus, Ohio, US; abstract no. 068654, BROWNFIELD R B: "Antiphlogistic pregnane derivatives" XP002061317 see abstract & ZA 6 704 880 - (AMERICAN CYANAMID CO.) 18 January 1968 --- -/--	1-11

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 97/05426

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 183 252 A (P. CRABBE) 11 May 1965 see whole document, in particular examples XIV-XVI	1-11
P,X	WO 97 34871 A (GARVEY DAVID S ;LETTS L GORDON (US); NITROMED INC (US); RENFROE H) 25 September 1997 see examples 4,5	1-11
E	WO 97 41144 A (SEARLE & CO ;TJOENG FOE S (US); CURRIE MARK G (US); ZUPEC MARK E ( ) 6 November 1997 see page 6	1-11
E	WO 97 40836 A (SEARLE & CO ;TJOENG FOE S (US); CURRIE MARK G (US); ZUPEC MARK E ( ) 6 November 1997 see claim 1	1-11

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL RCH REPORT

International application No.  
EP 97/05426

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

1. Claims: 1-11 (in part)

Compounds of the formula B-X1-NO<sub>2</sub>, where the nitrate group is attached via or to the 21-position of a pregnane derivative, pharmaceutical compositions thereof and their use in the manufacture of medicaments.

2. Claims: 1-11 (in part)

Compounds of the formula B-X1-NO<sub>2</sub>, where the nitrate group is attached to or via the 17-position where the steroid is not a pregnane derivative (i.e. not having a two carbon substituent in position 17.beta.), pharmaceutical compositions thereof and their use in the manufacture of medicaments.

3. Claims: 1-11 (in part)

Compounds of the formula B-X1-NO<sub>2</sub>, where the nitrate group is attached via the 11-position, pharmaceutical compositions thereof and their use in the manufacture of medicaments.

4. Claims: 1-11 (in part)

Compounds of the formula B-X1-NO<sub>2</sub>, where the nitrate group is attached via the 3-position, pharmaceutical compositions thereof and their use in the manufacture of medicaments.

5. Claims: 1-11 (in part)

Compounds of the formula B-X1-NO<sub>2</sub>, where the nitrate group is attached via the 16-position, pharmaceutical compositions thereof and their use in the manufacture of medicaments.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Invention No

PCT/EP 97/05426

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 2222491 A	16-11-72	AT 316767 B	15-06-74
		AT 331428 B	25-08-76
		AU 469581 B	19-02-76
		AU 4172272 A	08-11-73
		CA 975755 A	07-10-75
		CS 171259 B	29-10-76
		CS 171258 B	29-10-76
		DD 98668 A	05-07-73
		FR 2143664 A	09-02-73
		NL 7206134 A	09-11-72
		SE 385590 B	12-07-76
		SE 7503290 A	21-03-75
DE 1643034 A	06-05-71	NONE	
US 3494941 A	10-02-70	NONE	
FR 2274309 A	09-01-76	AT 357696 B	25-07-80
		AU 500060 B	10-05-79
		AU 7960375 A	30-09-76
		BE 827275 A	16-07-75
		CA 1065848 A	06-11-79
		CH 622811 A	30-04-81
		CH 625254 A	15-09-81
		DE 2512915 A	09-10-75
		DK 129575 A,B,	28-09-75
		DK 196776 A,B,	03-05-76
		GB 1510617 A	10-05-78
		GB 1511820 A	24-05-78
		HK 64679 A	21-09-79
		HK 64779 A	21-09-79
		JP 1247794 C	16-01-85
		JP 51115457 A	12-10-76
		JP 59022719 B	28-05-84
		JP 1327569 C	30-07-86
		JP 50157353 A	19-12-75
		JP 60043358 B	27-09-85
		JP 1435047 C	07-04-88
		JP 58189200 A	04-11-83
		JP 62041680 B	03-09-87

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

EP 97/05426

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2274309 A		NL 7503788 A,B, SE 418294 B SE 7503356 A SE 440656 B SE 7803041 A US 4024131 A ZA 7501599 A	30-09-75 18-05-81 29-09-75 12-08-85 16-03-78 17-05-77 25-02-76
US 2990401 A	27-06-61	NONE	
GB 1544512 A	19-04-79	US 3976637 A AU 506546 B AU 1738476 A BE 845943 A CA 1058161 A CH 618186 A CH 616437 A DE 2640490 A DK 402676 A FR 2322607 A JP 52033664 A NL 7609912 A SE 7609884 A	24-08-76 10-01-80 09-03-78 08-03-77 10-07-79 15-07-80 31-03-80 10-03-77 09-03-77 01-04-77 14-03-77 10-03-77 09-03-77
FR 1561908 A	04-04-69	CH 479565 A DE 1493318 A FR 4129 M GB 1054290 A NL 6404873 A NL 6404874 A US 3172896 A US 3209000 A	15-10-69 30-07-70  02-11-64 02-11-64 09-03-65 28-09-65
US 3183252 A	11-05-65	NONE	
WO 9734871 A	25-09-97	AU 2533697 A	10-10-97
WO 9741144 A	06-11-97	AU 2922797 A	19-11-97
WO 9740836 A	06-11-97	AU 2732597 A	19-11-97